Abstract
Background: IMPACT is a randomized, multicenter study (52 weeks) comparing the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs FF/VI and UMEC/VI in patients ≥40 years of age with symptomatic COPD and a history of exacerbations (exac) (N=10,355). For the primary endpoint, FF/UMEC/VI demonstrated a significant reduction in moderate (mod)/severe (sev) exac vs FF/VI and UMEC/VI (NEJM 2018;378:18). Objectives: Evaluate the overall benefit of FF/UMEC/VI by assessing outcomes across other COPD endpoints over time. Methods: Pre-specified endpoints were trough FEV1 (weeks 4, 16, 28, 40, 52) and SGRQ, TDI and CAT (weeks 4, 28, 52) analyzed by mixed models repeated measures. Results: FF/UMEC/VI vs FF/VI and UMEC/VI showed significant improvement in trough FEV1 (Figure) and SGRQ at week 4 that continued throughout the trial at all measured timepoints. FF/UMEC/VI demonstrated significant improvements in CAT vs FF/VI at all timepoints, and at weeks 4 and 52 compared to UMEC/VI. Conclusions: FF/UMEC/VI showed significant benefit across a range of COPD endpoints over time vs FF/VI and UMEC/VI. This underscores the consistent efficacy profile of FF/UMEC/VI and supports its role in the treatment of symptomatic patients with a history of exacerbations. Funding: GSK (Study CTT116855; NCT02164513).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
